Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study

• Veena Hoffman
• Jesper HallasUniversity of Southern Denmark
• Marie LinderKarolinska Institutet
• Andrea V. Margulis
• Brandon T. SuehsHumana (United States)
• Alejandro Arana
• Kelesitse Phiri
• Cheryl Enger
• Libby HorterHumana (United States)
• Ingvild OdsbuKarolinska Institutet
• Morten Salling OlesenUniversity of Southern Denmark
• Susana Perez‐Gutthann
• Yihua XuHumana (United States)
• Nina Sahlertz KristiansenUniversity of Southern Denmark
• Kwame AppentengAstellas Pharma (United States)
• Stefan de VogelAstellas Pharma (Netherlands)
• John D. Seeger
• the mirabegron PMR-PASS study group
• Cheryl Enger
• John D. Seeger
• Veena Hoffman
• Kelesitse PhiriUniversity of Southern Denmark
• Jesper HallasUniversity of Southern Denmark
• Morten OlesenUniversity of Southern Denmark
• Nina Sahlertz KristiansenUniversity of Southern Denmark
• Shahram BahmanyarKarolinska Institutet
• Marie LinderKarolinska Institutet
• Helle Kieler
• Ingvild OdsbuKarolinska Institutet
• Alejandro Arana
• Lisa J. McQuay
• Andrea V. Margulis
• Susana Perez-Gutthann
• RYAN M. ZIEMIECKIHumana (United States)
• Su BunniranHumana (United States)
• Brandon T. SuehsHumana (United States)
• Claudia UribeHumana (United States)
• Yihua XuHumana (United States)
• Libby HorterAstellas Pharma (United States)
• Kwame AppentengAstellas Pharma (Netherlands)
• Stefan de VogelAstellas Pharma (Netherlands)
• Noah Jamie Robinson
• Songlin Xue
• Josie Wolfram
• Achim Steup
• Jena Giese-Pagac
• Raymond van Aarle
• Neha Umesh Sheth
• David Burns
• Natalie Boone
• Mary Beth Blauwet
• Milbhor D’Silva
• Billy Franks
• Willem Jan Atsma
• Tim Auton
• Edeltraut Garbe
• Anders Ekbom
• Todd A. Lee
• Noel S. Weiss
• John S. Rumsfeld
• Sara Yuewen Gao
• Laura Karslake
• Nan Liu
• Katherine E. Reed
• Bruce Turnbull
• Jing Yang
• Nicole A. Brooks
• Kathleen Mortimer